Abstract: The invention relates to the use of a group of sigma receptor ligands of formula (I) for the potentiation of the analgesic effect of opioids and opiates and at the same time for decreasing the dependency induced by them.
Type:
Grant
Filed:
April 24, 2009
Date of Patent:
November 4, 2014
Assignee:
Laboratorios Del Dr. Esteve, S.A.
Inventors:
Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Daniel Zamanillo-Castanedo
Abstract: This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.
Type:
Grant
Filed:
October 16, 2012
Date of Patent:
October 28, 2014
Assignee:
Sanofi
Inventors:
Karl Schoenafinger, Henning Steinhagen, Bodo Scheiper, Uwe Heinelt, Volkmar Herrmann, Matthias Herrmann
Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
Type:
Grant
Filed:
August 20, 2012
Date of Patent:
October 28, 2014
Assignee:
Board of Regents, The University of Texas System
Abstract: A pharmaceutical solution, preferably a drinkable pharmaceutical solution of the active substance telmisartan is described, having a pH above 10 and additionally containing one or more sugar alcohols added to improve the flavour and shelf life, wherein the sugar alcohols or the pharmaceutical solution have a maximum content of 1000 ppm of reducing sugars.
Abstract: A Nutritional Supplement Composition promoting the increase, development, elevation and activation of the brain chemical “serotonin” in the “subjects” brain chemistry to improve mood, thought, emotions and, mental stability and functioning comprised of the constituents, Omega 3, Omega 6, Calcium Magnesium, and B-complex is described, as well as the method of administration, the usefulness of the present invention, and who would benefit from the administration of this present invention. This Nutritional Supplement composition may be used for all, in “age appropriate” dosages for different age “subjects”. This Nutritional Supplement Composition when administered daily will reduce and stabilize the “subjects” depression, anxiety, obsessive- compulsive behaviors stress related and other emotional and mental conditions. The above statement about the embodiment of the present invention will be further explained in more specific detail in the body of the description.
Abstract: Bioavailability of a ceramide, which is a minimally soluble material of a skin care composition exhibiting an excellent effect is enhanced by combining at least one component selected from ceramides represented by Formula (1): and at least one component selected from aliphatic alcohol having 12 to 30 carbon atoms.
Abstract: The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
October 14, 2014
Assignee:
Synaffix B.V.
Inventors:
Floris Louis van Delft, Floris Petrus Johannes Theodorus Rutjes, Frederik Jan Dommerholt
Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.
Abstract: The invention relates to the use of the compound hesperidin or of one of its derivatives for the manufacture of a composition designed to stimulate bone formation and/or inhibit bone resorption in man or animals.
Type:
Grant
Filed:
June 27, 2003
Date of Patent:
October 14, 2014
Assignee:
Institut National de la Recherche Agronomique (INRA)
Abstract: The present invention relates to salts, hydrates, and polymorphs of bicyclic heteroaryl compounds, and pharmaceutical compositions thereof, which may be useful as inhibitors of H4R for the treatment or prevention of diseases including allergic rhinitis.
Type:
Grant
Filed:
September 7, 2012
Date of Patent:
October 14, 2014
Assignee:
Kalypsys, Inc.
Inventors:
Pingyun Chen, Stephen A. R. Carino, Ricky Wayne Couch, Daniel S. Kinder, Beth A. Norton
Abstract: The present invention relates to 1.5 hydrate of of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.
Type:
Grant
Filed:
October 31, 2011
Date of Patent:
October 14, 2014
Assignee:
LG Life Sciences Ltd.
Inventors:
Ki Sook Park, Jung Min Yun, Bong Chan Kim, Kyu Young Kim, Ji Hye Lee
Abstract: The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
Type:
Grant
Filed:
September 7, 2007
Date of Patent:
October 7, 2014
Assignees:
Industrial Research Limited, Albert Einstein College of Medicine of Yeshiva University
Inventors:
Keith Clinch, Gary Brian Evans, Richard Hubert Furneaux, Shivali Ashwin Gulab, Peter Michael Kelly, Vern L. Schramm, Peter Charles Tyler, Anthony David Woolhouse
Abstract: The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
September 30, 2014
Assignee:
Ecolab USA Inc.
Inventors:
Junzhong Li, David D. McSherry, Richard Staub
Abstract: Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone.
Type:
Grant
Filed:
October 6, 2010
Date of Patent:
September 30, 2014
Assignees:
ConocoPhillips Company, University Technologies International, Inc.
Inventors:
Gary E. Jenneman, Anne Greene, Gerrit Voordouw
Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.
Abstract: Gemcabene, a carboxyalkylether, is effective in the treatment and prevention of pancreatitis in subjects. The compound can be administered in an effective dose as the free acid, a pharmaceutically acceptable salt, or an ester or pro-drug that is hydrolyzed or otherwise metabolized in situ to gemcabene as the free acid or salt thereof.
Abstract: A method for improving the sensory properties and resistance of food and drink products, especially uncured meat products, to various kinds of micro-organisms and in particular food spoilage and food poisoning bacteria includes contacting the food or drink product with a composition comprising alkali metal salts having as anions propionate and a co-anion selected from lactate, acetate, and combinations thereof, and as cations potassium and hydrogen, wherein the weight-based ratio of lactate/propionate is in the range of 0 to 20 and the weight-based ratio of acetate/propionate is in the range of 0.05 to 3.5.
Abstract: Compositions and methods for the treatment of premature ejaculation are provided wherein a composition comprising a topical anesthetic, a shear-thinning polymeric thickener, a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof, water and a buffer system that provides a buffered pH value for the composition in the range of about 3 to about 7.4 is administered to the penile meatus.
Type:
Grant
Filed:
March 22, 2004
Date of Patent:
September 23, 2014
Assignee:
Nexmed Holdings, Inc.
Inventors:
Mingqi Lu, Qin Wang, James L. Yeager, Y. Joseph Mo
Abstract: The invention provides a method for the treatment of fungal dermatitis. The treatment method involves administering an effective amount of luliconazole or a pharmaceutically acceptable salt thereof to a target in need of a treatment of fungal dermatitis.
Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Type:
Grant
Filed:
October 20, 2005
Date of Patent:
September 16, 2014
Assignee:
Endorecherche, Inc.
Inventors:
Mohamed El-Alfy, Fernand Labrie, Louise Berger